Newsroom
Saniona Icon blue
Latest News
November 25, 2021
PRESS RELEASE November 25 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the composition of the Nomination Committee for the Annual General Meeting 2022 . Pursuant to the instruction and charter for the Nomination Committee adopted
November 18, 2021
PRESS RELEASE November 18 , 202 1 Three Months Ended September 30, 2021 (2020) Revenue was SEK 2.3 M (2.2 M) Operating loss was SEK -88.2 M (-37.3 M) Net loss was SEK -93.7 M (-48.3 M) Basic loss per share was SEK -1.50 (-1.14) Diluted loss per share was SEK -1.50 (-1.14) Nine Months Ended
November 17, 2021
PRESS RELEASE November 1 7 , 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the initiation of a Phase 2b clinical trial of Tesomet in patients with hypothalamic obesity (HO). Tesomet is an investigational fixed-dose combination
If you have any questions regarding Saniona's media communication, feel free to contact us at any time.
trista morrison
Trista Morrison, Chief Communications Officer Phone: +1 781.810.9227 Email: trista.morrison@saniona.com